Eisai: new marketing subsidiary in Belgium

Japanese drug major Eisai has established a new European pharmaceutical marketing subsidiary in Brussels, Belgium, Eisai SA/NV, under the control of its London, UK-based Eisai Europe Ltd.

Serving as the regional sales hub for Benelux (Belgium, the Netherlands and Luxembourg), which is the sixth largest market in the European Union, the new Eisai unit will start marketing activities in all three countries in due course with the focus on the anti-epileptic drugs Zonegran (zonisamide) and Inovelon (rufinamide), as well as the non-opioid severe chronic pain agent Prialt (ziconotide). In addition, the firm plans to start promotion of its Alzheimer's disease treatment Aricept (donepezil) in Belgium and Luxembourg with its co-promotion partner. Eisai plans further expansion of its business operations across Europe and will undertake independent activities by using its own sales and marketing personnel, tailored for each county, it says.